1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
US4490381A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 29, 1980 |
| Grant date | Dec 25, 1984 |
| Priority date | — |
| Expiry date | Oct 29, 2000 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D209/38
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention concerns novel 1'-substituted spiro[imidazolidine-4,3'-indoline]-2,2',5-triones of the formula: ##STR1## in which R.sup.1 is (1-12C)alkyl; phenyl, naphthylmethyl or cinnamyl optionally bearing 1-2 halogeno substituents; or benzyl optionally bearing 1-3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)-alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; and ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or two substituents independently selected from halogeno (1-4C)alkyl and nitro; or a pharmaceutically acceptable salt thereof; but excluding those compounds wherein R.sup.1 is methyl, ethyl, n-propyl or unsubstituted benzyl and benzene ring A is unsubstituted. The compounds of the invention are potent inhibitors of the enzyme aldose reductase and are of use in the treatment or prophylaxis of certain complications of diabetes or galactosemia. The invention also embraces processes for the manufacture of the novel compounds of formula I, as well as pharmaceutical compositions of such compounds. A representative compound is 1'-(2-fluoro-4-bromobenzyl)-spiro]imidazolidine-4,3'-indoline]-2,2',5…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.